ap203
mAbexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Oct 14, 2022 (NCT06020001)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
TNFRSF9 inhibitor
- Programmed cell death 1 ligand 1INHIBITOR
CD274 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05473156 | Phase 1/Phase 2 (Phase 2) | Dec 31, 2022 | OBI Pharma, Inc |
| NCT06020001 | N/A | Oct 14, 2022 | AronPharma Sp. z o. o. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AronPharma Sp. z o. o. | For profit | 1 | 1 | 1 | 2022 |
| OBI Pharma, Inc | For profit | 1 | 1 | 1 | 2022 |
2 organizations
Page 1 / 1